Cardiff Oncology's Onvansertib Shows Durable Response, Progression-Free Survival In Colorectal Cancer Patients

Cardiff Oncology Inc CRDF has announced data from its ongoing Phase 1b/2 trial evaluating onvansertib combined with standard-of-care therapy in second-line KRAS-mutated metastatic colorectal cancer (mCRC).
Patients enrolled in the trial receive onvansertib combined with standard-of-care Folfiri Chemo and Roche Holdings AG's RHHBY Avastin (bevacizumab).
The overall response rate (ORR) in the trial is 39% to date, and onvansertib combined with Folfiri/bevacizumab has been well tolerated with no significant or unexpected toxicities attributed to onvansertib.
The median progression-free survival of evaluable patients is 9.4 months.
Clinical responses were observed across different KRAS mutations, including the three most common in colorectal cancer (G12D, G12V, G13D).
The greatest decreases in plasma KRAS mutant allelic frequency (MAF) after one treatment cycle were observed in patients achieving a PR.
All seven patients with a PR had a more than 75% decrease in KRAS MAF after one treatment cycle.
The updated Phase 1b/2 mCRC trial data will be presented during a key opinion leader webinar to be held today at 11:00 a.m. ET.
Price Action: CRDF shares are up 0.9% at $9.36 on the last check Monday.